A Multi-center, Open-label, Randomized, Study to Assess the Onset of Platelet Aggregation Inhibition After a Single Subcutaneous Injection of ACT-246475 in Adults With Acute Myocardial Infarction
Phase of Trial: Phase II
Latest Information Update: 19 Dec 2018
At a glance
- Drugs Selatogrel (Primary)
- Indications Myocardial infarction
- Focus Biomarker; Pharmacodynamics
- Sponsors Idorsia Pharmaceuticals
- 18 Dec 2018 According to an Idorsia media release, the compny will present data from this study at upcoming scientific congress and published in scientific literature.
- 18 Dec 2018 Results presented in an Idorsia media release.
- 18 Dec 2018 Primary endpoint has been met. (Inhibition of platelet aggregation), according to an Idorsia media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History